Preventive and Therapeutic Aspects of Migraine for Patient Care: An Insight

Ruchi      Tiwari; Gaurav      Tiwari; Sonam      Mishra; Vadivelan      Ramachandran
Abstract

Background: Migraine is a common neurological condition marked by frequent mild to extreme headaches that last 4 to 72 hours. A migraine headache may cause a pulsing or concentrated throbbing pain in one part of the brain. Nausea, vomiting, excessive sensitivity to light and sound, smell, feeling sick, vomiting, painful headache, and blurred vision are all symptoms of migraine disorder. Females are more affected by migraines in comparison to males.
Objective: The present review article summarizes preventive and therapeutic measures, including allopathic and herbal remedies for the treatment of migraine.
Results: This review highlights the current aspects of migraine pathophysiology and covers an understanding of the complex workings of the migraine state. Therapeutic agents that could provide an effective treatment have also been discussed.
Conclusion: It can be concluded that different migraines could be treated based on their type and severity.
Keywords: Migraines, treatment of migraines, preventive hemicrania medication, herbal remedies for migraines, herbal treatment, therapeutic treatment.
Graphical Abstract

[1]
Rasmussen, B.K.; Jensen, R.; Schroll, M.; Olesen, J. Epidemiology of headache in a general population-A prevalence study. J. Clin. Epidemiol.,  1991, 44(11), 1147-1157.
 [http://dx.doi.org/10.1016/0895-4356(91)90147-2] [PMID:  1941010]

[2]
Weitzel, K.W.; Thomas, M.L.; Small, R.E.; Goode, J.V.R. Migraine: A comprehensive review of new treatment options. Pharmacotherapy,  1999, 19(8), 957-973.
 [http://dx.doi.org/10.1592/phco.19.11.957.31569] [PMID:  10453967]

[3]
Villalón, C.M.; Centurión, D.; Valdivia, L.F.; De Vries, P.; Saxena, P.R. An introduction to migraine: From ancient treatment to functional pharmacology and antimigraine therapy. Proc. West. Pharmacol. Soc.,  2002, 45, 199-210.
 [PMID:  12434581]

[4]
Reed, K.L.; Black, S.B.; Banta, C.J., II; Will, K.R. Combined occipital and supraorbital neurostimulation for the treatment of chronic migraine headaches: Initial experience. Cephalalgia,  2010, 30(3), 260-271.
 [http://dx.doi.org/10.1111/j.1468-2982.2009.01996.x] [PMID:  19732075]

[5]
Tepper, S.J.; Stillman, M.J. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache,  2008, 48(8), 1259-1268.
 [http://dx.doi.org/10.1111/j.1526-4610.2008.01214.x] [PMID:  18808506]

[6]
Lipton, R.B.; Stewart, W.F. The epidemiology of migraine. Eur. Neurol.,  1994, 34(Suppl. 2), 6-11.
 [http://dx.doi.org/10.1159/000119525] [PMID:  7835383]

[7]
Wang, S.J. Epidemiology of migraine and other types of headache in Asia. Curr. Neurol. Neurosci. Rep.,  2003, 3(2), 104-108.
 [http://dx.doi.org/10.1007/s11910-003-0060-7] [PMID:  12583837]

[8]
Lipton, R.B.; Stewart, W.F.; Diamond, S.; Diamond, M.L.; Reed, M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache,  2001, 41(7), 646-657.
 [http://dx.doi.org/10.1046/j.1526-4610.2001.041007646.x] [PMID:  11554952]

[9]
Sheffield, R.E. Migraine prevalence: A literature review. Headache,  1998, 38(8), 595-601.
 [http://dx.doi.org/10.1046/j.1526-4610.1998.3808595.x] [PMID:  11398302]

[10]
Russell, M.B.; Iselius, L.; Olesen, J. Migraine without aura and migraine with aura are inherited disorders. Cephalalgia,  1996, 16(5), 305-309.
 [http://dx.doi.org/10.1046/j.1468-2982.1996.1605305.x] [PMID:  8869764]

[11]
Stewart, W.F.; Staffa, J.; Lipton, R.B.; Ottman, R. Familial risk of migraine: A population-based study. Ann. Neurol.,  1997, 41(2), 166-172.
 [http://dx.doi.org/10.1002/ana.410410207] [PMID:  9029065]

[12]
Larsson, B.; Bille, B.; Pedersen, N.L. Genetic influence in headaches: A Swedish twin study. Headache,  1995, 35(9), 513-519.
 [http://dx.doi.org/10.1111/j.1526-4610.1995.hed3509513.x] [PMID:  8530274]

[13]
Wöber-Bingöl, C. Epidemiology of migraine and headache in children and adolescents. Curr. Pain Headache Rep.,  2013, 17(6), 341.
 [http://dx.doi.org/10.1007/s11916-013-0341-z] [PMID:  23700075]

[14]
Arnold, M. Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia,  2018, 38(1), 1-211.
 [http://dx.doi.org/10.1177/0333102417738202] [PMID:  29368949]

[15]
Giffin, N.J.; Ruggiero, L.; Lipton, R.B.; Silberstein, S.D.; Tvedskov, J.F.; Olesen, J.; Altman, J.; Goadsby, P.J.; Macrae, A. Premonitory symptoms in migraine: An electronic diary study. Neurology,  2003, 60(6), 935-940.
 [http://dx.doi.org/10.1212/01.WNL.0000052998.58526.A9] [PMID:  12654956]

[16]
Kelman, L. The premonitory symptoms (prodrome): A tertiary care study of 893 migraineurs. Headache,  2004, 44(9), 865-872.
 [http://dx.doi.org/10.1111/j.1526-4610.2004.04168.x] [PMID:  15447695]

[17]
Rahimdel, A.; Mellat, A.; Zeinali, A.; Jafari, E.; Ayatollahi, P. Comparison between intravenous sodium valproate and subcutaneous sumatriptan for treatment of acute migraine attacks; double-blind randomized clinical trial. Iran. J. Med. Sci.,  2014, 39(2)(Suppl.), 171-177.
 [PMID:  24753639]

[18]
Rasmussen, B.K.; Olesen, J. Migraine with aura and migraine without aura: An epidemiological study. Cephalalgia,  1992, 12(4), 221-228.
 [http://dx.doi.org/10.1046/j.1468-2982.1992.1204221.x] [PMID:  1525797]

[19]
Amin, F.M.; Asghar, M.S.; Hougaard, A.; Hansen, A.E.; Larsen, V.A.; de Koning, P.J.; Larsson, H.B.; Olesen, J.; Ashina, M. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: A cross-sectional study. Lancet Neurol.,  2013, 12(5), 454-461.
 [http://dx.doi.org/10.1016/S1474-4422(13)70067-X] [PMID:  23578775]

[20]
Goadsby, P.J.; Holland, P.R.; Martins-Oliveira, M.; Hoffmann, J.; Schankin, C.; Akerman, S. Pathophysiology of migraine: A disorder of sensory processing. Physiol. Rev.,  2017, 97(2), 553-622.
 [http://dx.doi.org/10.1152/physrev.00034.2015] [PMID:  28179394]

[21]
Hargreaves, R.J.; Shepheard, S.L. Pathophysiology of migraine--new insights. Can. J. Neurol. Sci.,  1999, 26(3)(Suppl. 3), S12-S19.
 [http://dx.doi.org/10.1017/S0317167100000147] [PMID:  10563228]

[22]
Ferrari, M.D.; Klever, R.R.; Terwindt, G.M.; Ayata, C.; van den Maagdenberg, A.M. Migraine pathophysiology: Lessons from mouse models and human genetics. Lancet Neurol.,  2015, 14(1), 65-80.
 [http://dx.doi.org/10.1016/S1474-4422(14)70220-0] [PMID:  25496898]

[23]
Martin, V.T.; Behbehani, M.M. Toward a rational understanding of migraine trigger factors. Med. Clin. North Am.,  2001, 85(4), 911-941.
 [http://dx.doi.org/10.1016/S0025-7125(05)70351-5] [PMID:  11480265]

[24]
Lantéri-Minet, M.; Desnuelle, C. Migraine and mitochondrial dysfunction. Rev. Neurol. (Paris),  1996, 152(4), 234-238.
 [PMID:  8763651]

[25]
Koo, B.; Becker, L.E.; Chuang, S.; Merante, F.; Robinson, B.H.; MacGregor, D.; Tein, I.; Ho, V.B.; McGreal, D.A.; Wherrett, J.R. Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): Clinical, radiological, pathological, and genetic observations. Ann. Neurol.,  1993, 34(1), 25-32.
 [http://dx.doi.org/10.1002/ana.410340107] [PMID:  8517676]

[26]
Bresolin, N.; Martinelli, P.; Barbiroli, B.; Zaniol, P.; Ausenda, C.; Montagna, P.; Gallanti, A.; Comi, G.P.; Scarlato, G.; Lugaresi, E. Muscle mitochondrial DNA deletion and 31P-NMR spectroscopy alterations in a migraine patient. J. Neurol. Sci.,  1991, 104(2), 182-189.
 [http://dx.doi.org/10.1016/0022-510X(91)90308-T] [PMID:  1658240]

[27]
Montagna, P.; Cortelli, P.; Barbiroli, B. Magnetic resonance spectroscopy studies in migraine. Cephalalgia,  1994, 14(3), 184-193.
 [http://dx.doi.org/10.1046/j.1468-2982.1994.014003184.x] [PMID:  7954737]

[28]
Goadsby, P.J.; Lipton, R.B.; Ferrari, M.D. Migraine--current understanding and treatment. N. Engl. J. Med.,  2002, 346(4), 257-270.
 [http://dx.doi.org/10.1056/NEJMra010917] [PMID:  11807151]

[29]
Coppola, G.; Di Renzo, A.; Tinelli, E.; Iacovelli, E.; Lepre, C.; Di Lorenzo, C.; Di Lorenzo, G.; Di Lenola, D.; Parisi, V.; Serrao, M.; Pauri, F.; Fiermonte, G.; Bianco, F.; Pierelli, F. Evidence for brain morphometric changes during the migraine cycle: A magnetic resonance-based morphometry study. Cephalalgia,  2015, 35(9), 783-791.
 [http://dx.doi.org/10.1177/0333102414559732] [PMID:  25414472]

[30]
Rizzoli, P.B. Acute and preventive treatment of migraine. Continuum (Minneap. Minn.),  2012, 18(4), 764-782.
 [http://dx.doi.org/10.1212/01.CON.0000418641.45522.3b] [PMID:  22868540]

[31]
Gladstone, J.P.; Eross, E.J.; Dodick, D.W. Migraine in special populations. Treatment strategies for children and adolescents, pregnant women, and the elderly. Postgrad. Med.,  2004, 115(4), 39-44, 47-50.
 [http://dx.doi.org/10.3810/pgm.2004.04.1479] [PMID:  15095535]

[32]
Haan, J.; Hollander, J.; Ferrari, M.D. Migraine in the elderly: A review. Cephalalgia,  2007, 27(2), 97-106.
 [http://dx.doi.org/10.1111/j.1468-2982.2006.01250.x] [PMID:  17257228]

[33]
Burris, J.E. Pharmacologic approaches to geriatric pain management. Arch. Phys. Med. Rehabil.,  2004, 85(7)(Suppl. 3), S45-S49.
 [http://dx.doi.org/10.1016/j.apmr.2004.03.011] [PMID:  15221725]

[34]
Young, N.; Silverman, D.; Bradford, H.; Finkelstein, J. Multicenter prevalence of opioid medication use as abortive therapy in the ED treatment of migraine headaches. Am. J. Emerg. Med.,  2017, 35(12), 1845-1849.
 [http://dx.doi.org/10.1016/j.ajem.2017.06.015] [PMID:  28645559]

[35]
Edmeads, J. Headaches in older people. How are they different in this age-group? Postgrad. Med.,  1997, 101(5), 91-94, 98-100.
 [http://dx.doi.org/10.3810/pgm.1997.05.239] [PMID:  9158609]

[36]
Loder, E. Triptan therapy in migraine. N. Engl. J. Med.,  2010, 363(1), 63-70.
 [http://dx.doi.org/10.1056/NEJMct0910887] [PMID:  20592298]

[37]
Tfelt-Hansen, P.; Saxena, P.R.; Dahlöf, C.; Pascual, J.; Láinez, M.; Henry, P.; Diener, H.; Schoenen, J.; Ferrari, M.D.; Goadsby, P.J. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain,  2000, 123(Pt 1), 9-18.
 [http://dx.doi.org/10.1093/brain/123.1.9] [PMID:  10611116]

[38]
Hall, G.C.; Brown, M.M.; Mo, J.; MacRae, K.D. Triptans in migraine: The risks of stroke, cardiovascular disease, and death in practice. Neurology,  2004, 62(4), 563-568.
 [http://dx.doi.org/10.1212/01.WNL.0000110312.36809.7F] [PMID:  14981171]

[39]
Cabarrocas, X.; Jansat, J.M.; Ferrer, P.; Luria, X. Pharmacokinetics of oral almotriptan during and outside a migraine attack. Cephalalgia,  2000, 20(4), 417.

[40]
Andersen, A.R.; Tfelt-Hansen, P.; Lassen, N.A. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke,  1987, 18(1), 120-123.
 [http://dx.doi.org/10.1161/01.STR.18.1.120] [PMID:  3810743]

[41]
Peck, R.W.; Seaber, E.J.; Dixon, R.M.; Layton, G.R.; Weatherley, B.C.; Jackson, S.H.; Rolan, P.E.; Posner, J. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clin. Pharmacol. Ther.,  1998, 63(3), 342-353.
 [http://dx.doi.org/10.1016/S0009-9236(98)90166-7] [PMID:  9542478]

[42]
Rahimtoola, H.; Buurma, H.; Tijssen, C.C.; Leufkens, H.G.; Egberts, A.C.G. Migraine prophylactic medication usage patterns in The Netherlands. Cephalalgia,  2003, 23(4), 293-301.
 [http://dx.doi.org/10.1046/j.1468-2982.2003.00494.x] [PMID:  12716348]

[43]
Silberstein, S.D. Preventive migraine treatment. Neurol. Clin.,  2009, 27(2), 429-443.
 [http://dx.doi.org/10.1016/j.ncl.2008.11.007] [PMID:  19289224]

[44]
Bahra, A. Primary headache disorders: Focus on migraine. Pain Rev.,  2011, 5(4), 2-11.
 [http://dx.doi.org/10.1177/204946371100500402] [PMID:  26525886]

[45]
Silberstein, S.D. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards subcommittee of the american academy of neurology. Neurology,  2000, 55(6), 754-762.
 [http://dx.doi.org/10.1212/WNL.55.6.754] [PMID:  10993991]

[46]
Andersson, K.E. Vinge, E. β-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs,  1990, 39(3), 355-373.
 [http://dx.doi.org/10.2165/00003495-199039030-00003] [PMID:  1970289]

[47]
Ekbom, K. Alprenolol for migraine prophylaxis. Headache,  1975, 15(2), 129-132.
 [http://dx.doi.org/10.1111/j.1526-4610.1975.hed1502129.x] [PMID:  1097368]

[48]
Burch, R.; Rizzoli, P.; Loder, E. The prevalence and impact of migraine and severe headache in the United States: Figures and trends from government health studies. Headache,  2018, 58(4), 496-505.
 [http://dx.doi.org/10.1111/head.13281] [PMID:  29527677]

[49]
Chronicle, E.; Mulleners, W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst. Rev.,  2004, (3), CD003226.
 [PMID:  15266476]

[50]
Arroyo, S.; Kramer, G. Treating epilepsy in the elderly: Safety considerations. Drug Saf.,  2001, 24(13), 991-1015.
 [http://dx.doi.org/10.2165/00002018-200124130-00006] [PMID:  11735655]

[51]
Brandes, J.L.; Saper, J.R.; Diamond, M.; Couch, J.R.; Lewis, D.W.; Schmitt, J.; Neto, W.; Schwabe, S.; Jacobs, D. Topiramate for migraine prevention: A randomized controlled trial. JAMA,  2004, 291(8), 965-973.
 [http://dx.doi.org/10.1001/jama.291.8.965] [PMID:  14982912]

[52]
Grošelj, J.; Guerrini, R.; Van Oene, J.; Lahaye, M.; Schreiner, A.; Schwalen, S. Experience with topiramate monotherapy in elderly patients with recent-onset epilepsy. Acta Neurol. Scand.,  2005, 112(3), 144-150.
 [http://dx.doi.org/10.1111/j.1600-0404.2005.00469.x] [PMID:  16097955]

[53]
Schrader, H.; Stovner, L.J.; Helde, G.; Sand, T.; Bovim, G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ,  2001, 322(7277), 19-22.
 [http://dx.doi.org/10.1136/bmj.322.7277.19] [PMID:  11141144]

[54]
Diamond, S.; Bigal, M.E.; Silberstein, S.; Loder, E.; Reed, M.; Lipton, R.B. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: Results from the American Migraine Prevalence and Prevention study. Headache,  2007, 47(3), 355-363.
 [PMID:  17371352]

[55]
Owada, K. Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens. Res.,  2004, 27(6), 441-446.
 [http://dx.doi.org/10.1291/hypres.27.441] [PMID:  15253110]

[56]
Cunningham, E.T., Jr; Bohn, M.C.; Sawchenko, P.E. Organization of adrenergic inputs to the paraventricular and supraoptic nuclei of the hypothalamus in the rat. J. Comp. Neurol.,  1990, 292(4), 651-667.
 [http://dx.doi.org/10.1002/cne.902920413] [PMID:  2324319]

[57]
Bigal, M.E.; Serrano, D.; Buse, D.; Scher, A.; Stewart, W.F.; Lipton, R.B. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache,  2008, 48(8), 1157-1168.
 [http://dx.doi.org/10.1111/j.1526-4610.2008.01217.x] [PMID:  18808500]

[58]
Diener, H.C.; Charles, A.; Goadsby, P.J.; Holle, D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol.,  2015, 14(10), 1010-1022.
 [http://dx.doi.org/10.1016/S1474-4422(15)00198-2] [PMID:  26376968]

[59]
Jivad, N.; Asadi-Samani, M.; Moradi, M.T. The most important medicinal plants effective on migraine: A review of ethnobotanical studies in Iran. Pharma Chem.,  2016, 8(2), 462-466.

[60]
Rajapakse, T.; Davenport, W.J. Phytomedicines in the treatment of migraine. CNS Drugs,  2019, 33(5), 399-415.
 [http://dx.doi.org/10.1007/s40263-018-0597-2] [PMID:  30627973]

[61]
da Fonsêca, D.V.; da Silva Maia Bezerra Filho, C.; Lima, T.C.; de Almeida, R.N.; de Sousa, D.P. Anticonvulsant essential oils and their relationship with oxidative stress in epilepsy. Biomolecules,  2019, 9(12), 835.
 [http://dx.doi.org/10.3390/biom9120835] [PMID:  31817682]

[62]
Taherian, A.A.; Vafaei, A.A.; Ameri, J. Opiate system mediates the antinociceptive effects of Coriandrum sativum in mice. Iran. J. Pharm. Res.,  2012, 11(2), 679-688.
 [PMID:  24250493]

[63]
Bahmani, M.; Eftekhari, Z.; Jelodari, M.; Saki, K.; Abdollahi, R.; Majlesi, M.; Rasouli, S. Effect of Iranian herbal medicines in dysmenorrhea phytotherapy. J. Chem. Pharm. Res.,  2015, (2), 519-526.

[64]
Nasri, H.; Tavakoli, M.; Ahmadi, A.; Baradaran, A.; Nematbakhsh, M.; Rafieian-Kopaei, M. Ameliorative effect of melatonin against contrast media induced renal tubular cell injury. Pak. J. Med. Sci.,  2014, 30(2), 261-265.
 [PMID:  24772123]

[65]
Diener, H.C. Headache: Insight, understanding, treatment and patient management. Int. J. Clin. Pract. Suppl.,  2013, 67(178), 33-36.
 [http://dx.doi.org/10.1111/ijcp.12049] [PMID:  23163546]

[66]
Delaruelle, Z.; Ivanova, T.A.; Khan, S.; Negro, A.; Ornello, R.; Raffaelli, B.; Terrin, A.; Mitsikostas, D.D.; Reuter, U. Male and female sex hormones in primary headaches. J. Headache Pain,  2018, 19(1), 117.
 [http://dx.doi.org/10.1186/s10194-018-0922-7] [PMID:  30497379]

[67]
Gruia, F.S. Biological treatment of pain. Results of a doctor’s practice study with a phytopharmaceutical. Erfahrungsheilkunde,  1986, 35, 396-401.

[68]
Gruia, F.S. Pflanzliche Analgetika-Therapie bei WS-Syndrom. Biol. Med.,  1987, 3, 454.

[69]
Barsom, S. Behandlung von Koliken und Spasmen in der Urologie mit einem pflanzlichen Spasmolytikum. Erfahrungsheilkunde,  1986, 35, 1-11.

[70]
Ziolo, G.; Samochowiec, L. Study on clinical properties and mechanisms of action of Petasites in bronchial asthma and chronic obstructive bronchitis. Pharm. Acta Helv.,  1998, 72(6), 378-380.
 [PMID:  9556439]

[71]
Pothmann, R.; Danesch, U. Migraine prevention in children and adolescents: Results of an open study with a special butterbur root extract. Headache,  2005, 45(3), 196-203.
 [http://dx.doi.org/10.1111/j.1526-4610.2005.05044.x] [PMID:  15836592]

[72]
Thomet, O.A.; Wiesmann, U.N.; Schapowal, A.; Bizer, C.; Simon, H.U. Role of petasin in the potential anti-inflammatory activity of a plant extract of petasites hybridus. Biochem. Pharmacol.,  2001, 61(8), 1041-1047.
 [http://dx.doi.org/10.1016/S0006-2952(01)00552-4] [PMID:  11286996]

[73]
Maizels, M.; Blumenfeld, A.; Burchette, R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: A randomized trial. Headache,  2004, 44(9), 885-890.
 [http://dx.doi.org/10.1111/j.1526-4610.2004.04170.x] [PMID:  15447697]

[74]
Hwang, D.; Fischer, N.H.; Jang, B.C.; Tak, H.; Kim, J.K.; Lee, W. Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem. Biophys. Res. Commun.,  1996, 226(3), 810-818.
 [http://dx.doi.org/10.1006/bbrc.1996.1433] [PMID:  8831694]

[75]
Krone, D.; Mannel, M.; Pauli, E.; Hummel, T. Qualitative and quantitative olfactometric evaluation of different concentrations of ethanol peppermint oil solutions. Phytother. Res.,  2001, 15(2), 135-138.
 [http://dx.doi.org/10.1002/ptr.716] [PMID:  11268113]

[76]
Borhani Haghighi, A.; Motazedian, S.; Rezaii, R.; Mohammadi, F.; Salarian, L.; Pourmokhtari, M.; Khodaei, S.; Vossoughi, M.; Miri, R. Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: A randomised, double-blind, placebo-controlled, crossed-over study. Int. J. Clin. Pract.,  2010, 64(4), 451-456.
 [http://dx.doi.org/10.1111/j.1742-1241.2009.02215.x] [PMID:  20456191]

[77]
Rafieian-Kopaei, M.; Hasanpour-Dehkordi, A.; Lorigooini, Z.; Deris, F.; Solati, K.; Mahdiyeh, F. Comparing the effect of intranasal lidocaine 4% with peppermint essential oil drop 1.5% on migraine attacks: A double-blind clinical trial. Int. J. Prev. Med.,  2019, 10(10), 121.
 [PMID:  31404204]

[78]
Mustafa, T.; Srivastava, K.C. Ginger (Zingiber officinale) in migraine headache. J. Ethnopharmacol.,  1990, 29(3), 267-273.
 [http://dx.doi.org/10.1016/0378-8741(90)90037-T] [PMID:  2214812]

[79]
Abascal, K.; Yarnell, E. Clinical uses of Zingiber officinale (ginger). Altern. Complement. Ther.,  2009, 15(5), 231-237.
 [http://dx.doi.org/10.1089/act.2009.15501]

[80]
Sahib, N.G.; Anwar, F.; Gilani, A.H.; Hamid, A.A.; Saari, N.; Alkharfy, K.M. Coriander (Coriandrum sativum L.): A potential source of high-value components for functional foods and nutraceuticals--a review. Phytother. Res.,  2013, 27(10), 1439-1456.
 [http://dx.doi.org/10.1002/ptr.4897] [PMID:  23281145]

[81]
Hosseinzadeh, H.; Madanifard, M. Anticonvulsant effects of Coriandrum sativum L. seed extracts in mice. Arch. Iran Med.,  2000, 3(4), 81-84.

[82]
Nowaczewska, M. Wiciński, M.; Kaźmierczak, W. The ambiguous role of caffeine in migraine headache: From trigger to treatment. Nutrients,  2020, 12(8), 2259.
 [http://dx.doi.org/10.3390/nu12082259] [PMID:  32731623]

[83]
Grant, E.C. Food allergies and migraine. Lancet,  1979, 1(8123), 966-969.
 [http://dx.doi.org/10.1016/S0140-6736(79)91735-5] [PMID:  87628]

[84]
Jacobs, B.; Dussor, G. Neurovascular contributions to migraine: Moving beyond vasodilation. Neuroscience,  2016, 338, 130-144.
 [http://dx.doi.org/10.1016/j.neuroscience.2016.06.012] [PMID:  27312704]

[85]
Jahromi, S.R.; Ghorbani, Z.; Martelletti, P.; Lampl, C.; Togha, M. Association of diet and headache. J. Headache Pain,  2019, 20(1), 1-11.
 [PMID:  30616570]

[86]
Buchbauer, G.; Jirovetz, L.; Jäger, W.; Dietrich, H.; Plank, C. Aromatherapy: Evidence for sedative effects of the essential oil of lavender after inhalation. Z. Naturforsch. C J. Biosci.,  1991, 46(11-12), 1067-1072.
 [http://dx.doi.org/10.1515/znc-1991-11-1223] [PMID:  1817516]

[87]
Sasannejad, P.; Saeedi, M.; Shoeibi, A.; Gorji, A.; Abbasi, M.; Foroughipour, M. Lavender essential oil in the treatment of migraine headache: A placebo-controlled clinical trial. Eur. Neurol.,  2012, 67(5), 288-291.
 [http://dx.doi.org/10.1159/000335249] [PMID:  22517298]

[88]
Rafie, S.; Namjoyan, F.; Golfakhrabadi, F.; Yousefbeyk, F.; Hassanzadeh, A. Effect of lavender essential oil as a prophylactic therapy for migraine: A randomized controlled clinical trial. J. Herb. Med.,  2016, 6(1), 18-23.
 [http://dx.doi.org/10.1016/j.hermed.2016.01.003]

[89]
Gedney, J.J.; Glover, T.L.; Fillingim, R.B. Sensory and affective pain discrimination after inhalation of essential oils. Psychosom. Med.,  2004, 66(4), 599-606.
 [http://dx.doi.org/10.1097/01.psy.0000132875.01986.47] [PMID:  15272109]

[90]
Koto, R.; Imamura, M.; Watanabe, C.; Obayashi, S.; Shiraishi, M.; Sasaki, Y.; Azuma, H. Linalyl acetate as a major ingredient of lavender essential oil relaxes the rabbit vascular smooth muscle through dephosphorylation of myosin light chain. J. Cardiovasc. Pharmacol.,  2006, 48(1), 850-856.
 [http://dx.doi.org/10.1097/01.fjc.0000238589.00365.42] [PMID:  16891914]

[91]
Inouye, S.; Takizawa, T.; Yamaguchi, H. Antibacterial activity of essential oils and their major constituents against respiratory tract pathogens by gaseous contact. J. Antimicrob. Chemother.,  2001, 47(5), 565-573.
 [http://dx.doi.org/10.1093/jac/47.5.565] [PMID:  11328766]

[92]
Olesen, J.; Diener, H.C.; Husstedt, I.W.; Goadsby, P.J.; Hall, D.; Meier, U.; Pollentier, S.; Lesko, L.M. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med.,  2004, 350(11), 1104-1110.
 [http://dx.doi.org/10.1056/NEJMoa030505] [PMID:  15014183]

[93]
Denner, S.S. Lavandula angustifolia Miller: English lavender. Holist. Nurs. Pract.,  2009, 23(1), 57-64.
 [http://dx.doi.org/10.1097/01.HNP.0000343210.56710.fc] [PMID:  19104276]

[94]
Prashar, A.; Locke, I.C.; Evans, C.S. Cytotoxicity of lavender oil and its major components to human skin cells. Cell Prolif.,  2004, 37(3), 221-229.
 [http://dx.doi.org/10.1111/j.1365-2184.2004.00307.x] [PMID:  15144499]

[95]
Vakilian, K.; Atarha, M.; Bekhradi, R.; Chaman, R. Healing advantages of lavender essential oil during episiotomy recovery: A clinical trial. Complement. Ther. Clin. Pract.,  2011, 17(1), 50-53.
 [http://dx.doi.org/10.1016/j.ctcp.2010.05.006] [PMID:  21168115]

[96]
Vila-Pueyo, M.; Strother, L.; Page, K.; Loaraine, H.; Kovalchin, J.; Goadsby, P.J.; Holland, P.R. Lasmiditan inhibits trigeminovascular nociceptive transmission. Cephalalgia,  2016, 36, 152.

[97]
Azizi, H.; Shojaii, A.; Hashem-Dabaghian, F.; Noras, M.; Boroumand, A.; Ebadolahzadeh Haghani, B.; Ghods, R. Effects of Valeriana officinalis (Valerian) on tension-type headache: A randomized, placebo-controlled, double-blind clinical trial. Avicenna J. Phytomed.,  2020, 10(3), 297-304.
 [PMID:  32523884]

[98]
Jia, J.N.; Zhang, B.H. Effect of valerian extract (V3d) on cardiovascular system. J. Guangxi. Coll. Tradit. Chin. Med.,  1999, 16, 40-42.

[99]
Oshima, Y.; Matsuoka, S.; Ohizumi, Y. Antidepressant principles of Valeriana fauriei roots. Chem. Pharm. Bull. (Tokyo),  1995, 43(1), 169-170.
 [http://dx.doi.org/10.1248/cpb.43.169] [PMID:  7895306]

[100]
Becker, H.; Chavadej, S. Valepotriate production of normal and colchicine-treated cell suspension cultures of Valeriana wallichii. J. Nat. Prod.,  1985, 48(1), 17-21.
 [http://dx.doi.org/10.1021/np50037a003] [PMID:  4009183]

[101]
Mirzaee, M.G.; Kheiri, S.; Bahrami, M. Effect of valerian capsules in patients with migraine attacks treated with sodium valproate: A randomized clinical trial. Shahrekord Univ. Med. Sci. J.,  2015, 16(6), 119-126.

[102]
Buse, D.; Manack, A.; Serrano, D.; Reed, M.; Varon, S.; Turkel, C.; Lipton, R. Headache impact of chronic and episodic migraine: Results from the American Migraine Prevalence and Prevention study. Headache,  2012, 52(1), 3-17.
 [http://dx.doi.org/10.1111/j.1526-4610.2011.02046.x] [PMID:  22106869]

[103]
Abebe, W. Herbal medication: Potential for adverse interactions with analgesic drugs. J. Clin. Pharm. Ther.,  2002, 27(6), 391-401.
 [http://dx.doi.org/10.1046/j.1365-2710.2002.00444.x] [PMID:  12472978]

[104]
Ang-Lee, M.K.; Moss, J.; Yuan, C.S. Herbal medicines and perioperative care. JAMA,  2001, 286(2), 208-216.
 [http://dx.doi.org/10.1001/jama.286.2.208] [PMID:  11448284]

[105]
Shorr, R.I.; Ray, W.A.; Daugherty, J.R.; Griffin, M.R. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch. Intern. Med.,  1993, 153(14), 1665-1670.
 [http://dx.doi.org/10.1001/archinte.1993.00410140047006] [PMID:  8333804]

[106]
Kunnumakkara, A.B.; Bordoloi, D.; Padmavathi, G.; Monisha, J.; Roy, N.K.; Prasad, S.; Aggarwal, B.B. Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases. Br. J. Pharmacol.,  2017, 174(11), 1325-1348.
 [http://dx.doi.org/10.1111/bph.13621] [PMID:  27638428]

[107]
Aggarwal, B.B.; Kumar, A.; Bharti, A.C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res.,  2003, 23(1/A), 363-398.

[108]
Xu, X.Y.; Meng, X.; Li, S.; Gan, R.Y.; Li, Y.; Li, H.B. Bioactivity, health benefits, and related molecular mechanisms of curcumin: Current progress, challenges, and perspectives. Nutrients,  2018, 10(10), 1553.
 [http://dx.doi.org/10.3390/nu10101553] [PMID:  30347782]

[109]
Goschorska, M.; Gutowska, I.; Baranowska-Bosiacka, I.; Barczak, K.; Chlubek, D. The use of antioxidants in the treatment of migraine. Antioxidants,  2020, 9(2), 116.
 [http://dx.doi.org/10.3390/antiox9020116] [PMID:  32012936]

[110]
Bulboacă, A.E.; Bolboacă, S.D.; Stă,nescu, I.C.; Sfrângeu, C.A.; Porfire, A.; Tefas, L.; Bulboacă, A.C. The effect of intravenous administration of liposomal curcumin in addition to sumatriptan treatment in an experimental migraine model in rats. Int. J. Nanomedicine,  2018, 13, 3093-3103.
 [http://dx.doi.org/10.2147/IJN.S162087] [PMID:  29872296]

[111]
Jafarpour, M.; Yousefi, G.; Hamedi, A.; Shariat, A.; Salehi, A.; Heydari, M. Effect of a traditional syrup from Citrus medica L. fruit juice on migraine headache: A randomized double blind placebo controlled clinical trial. J. Ethnopharmacol.,  2016, 179, 170-176.
 [http://dx.doi.org/10.1016/j.jep.2015.12.040] [PMID:  26721220]

[112]
Gilmore, B.; Michael, M. Treatment of acute migraine headache. Am. Fam. Physician,  2011, 83(3), 271-280.
 [PMID:  21302868]

[113]
Mina, C.N.; Farzaei, M.H.; Gholamreza, A. Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: A review. J. Tradit. Chin. Med.,  2015, 35(1), 104-109.
 [http://dx.doi.org/10.1016/S0254-6272(15)30016-9] [PMID:  25842736]

[114]
Boyd, A.; Bleakley, C.; Hurley, D.A.; Gill, C.; Hannon-Fletcher, M.; Bell, P.; McDonough, S. Herbal medicinal products or preparations for neuropathic pain. Cochrane Database Syst. Rev.,  2019, 4(4), CD010528.
 [PMID:  30938843]

[115]
Niazi, M.; Hashempur, M.H.; Taghizadeh, M.; Heydari, M.; Shariat, A. Efficacy of topical Rose (Rosa damascena Mill.) oil for migraine headache: A randomized double-blinded placebo-controlled cross-over trial. Complement. Ther. Med.,  2017, 34, 35-41.
 [http://dx.doi.org/10.1016/j.ctim.2017.07.009] [PMID:  28917373]

[116]
Hashempur, M.H.; Ghasemi, M.S.; Daneshfard, B.; Ghoreishi, P.S.; Lari, Z.N.; Homayouni, K.; Zargaran, A. Efficacy of topical chamomile oil for mild and moderate carpal tunnel syndrome: A randomized double-blind placebo-controlled clinical trial. Complement. Ther. Clin. Pract.,  2017, 26, 61-67.
 [http://dx.doi.org/10.1016/j.ctcp.2016.11.010] [PMID:  28107852]

[117]
D’Andrea, G.; Cevoli, S.; Cologno, D. Herbal therapy in migraine. Neurol. Sci.,  2014, 35(Suppl. 1), 135-140.
 [http://dx.doi.org/10.1007/s10072-014-1757-x] [PMID:  24867850]

[118]
Zargaran, A.; Borhani-Haghighi, A.; Faridi, P.; Daneshamouz, S.; Kordafshari, G.; Mohagheghzadeh, A. Potential effect and mechanism of action of topical chamomile (Matricaria chammomila L.) oil on migraine headache: A medical hypothesis. Med. Hypotheses,  2014, 83(5), 566-569.
 [http://dx.doi.org/10.1016/j.mehy.2014.08.023] [PMID:  25238714]

[119]
Zargaran, A.; Borhani-Haghighi, A.; Salehi-Marzijarani, M.; Faridi, P.; Daneshamouz, S.; Azadi, A.; Sadeghpour, H.; Sakhteman, A.; Mohagheghzadeh, A. Evaluation of the effect of topical chamomile (Matricaria chamomilla L.) oleogel as pain relief in migraine without aura: A randomized, double-blind, placebo-controlled, crossover study. Neurol. Sci.,  2018, 39(8), 1345-1353.
 [http://dx.doi.org/10.1007/s10072-018-3415-1] [PMID:  29808331]

[120]
Lee, J.S.; Jeong, M.; Park, S.; Ryu, S.M.; Lee, J.; Song, Z.; Guo, Y.; Choi, J.H.; Lee, D.; Jang, D.S. Chemical constituents of the leaves of butterbur (Petasites japonicus) and their anti-inflammatory effects. Biomolecules,  2019, 9(12), 806.
 [http://dx.doi.org/10.3390/biom9120806] [PMID:  31795455]

[121]
Pareek, A.; Suthar, M.; Rathore, G.S.; Bansal, V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn. Rev.,  2011, 5(9), 103-110.
 [http://dx.doi.org/10.4103/0973-7847.79105] [PMID:  22096324]

[122]
Loolaie, M.; Moasefi, N.; Rasouli, H. Peppermint and its functionality: A review. Arch. Clin. Microbiol.,  2011, 8(4), 54.

[123]
Kemper, K.J. Ginger (Zingiber officinale). Longwood Herbal Task Force,  1999, 3, 1-18.

[124]
Laribi, B.; Kouki, K.; M’Hamdi, M.; Bettaieb, T. Coriander (Coriandrum sativum L.) and its bioactive constituents. Fitoterapia,  2015, 103, 9-26.
 [http://dx.doi.org/10.1016/j.fitote.2015.03.012] [PMID:  25776008]

[125]
Nehlig, A. Effects of coffee/caffeine on brain health and disease: What should I tell my patients? Pract. Neurol.,  2016, 16(2), 89-95.
 [http://dx.doi.org/10.1136/practneurol-2015-001162] [PMID:  26677204]

[126]
ALAsmari, K.M.; Zeid, I.M.A.; Al-Attar, A.M. Medicinal properties of Arabica coffee (Coffea arabica) oil: An overview. Adv. Life Sci.,  2020, 8(1), 20-29.

[127]
Nandhini, S.; Narayanan, K.B.; Ilango, K. Valeriana Officinalis: A review of its traditional uses, phytochemistry and pharmacology. Asian J. Pharm. Clin. Res.,  2018, 11(1), 36-41.
 [http://dx.doi.org/10.22159/ajpcr.2018.v11i1.22588]

[128]
Wei, W.L.; Zeng, R.; Gu, C.M.; Qu, Y.; Huang, L.F. Angelica sinensis in China-A review of botanical profile, ethnopharmacology, phytochemistry and chemical analysis. J. Ethnopharmacol.,  2016, 190, 116-141.
 [http://dx.doi.org/10.1016/j.jep.2016.05.023] [PMID:  27211015]

[129]
Singh, O.; Khanam, Z.; Misra, N.; Srivastava, M.K. Chamomile (Matricaria chamomilla L.): An overview. Pharmacogn. Rev.,  2011, 5(9), 82-95.
 [http://dx.doi.org/10.4103/0973-7847.79103] [PMID:  22096322]

[130]
Zorofchian Moghadamtousi, S.; Abdul Kadir, H.; Hassandarvish, P.; Tajik, H.; Abubakar, S.; Zandi, K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res. Int., 2014, 2014.
 [http://dx.doi.org/10.1155/2014/186864]

[131]
Hewlings, S.J.; Kalman, D.S. Curcumin: A review of its effects on human health. Foods,  2017, 6(10), 92.
 [http://dx.doi.org/10.3390/foods6100092] [PMID:  29065496]

[132]
Izzo, A.A. Herb-drug interactions: An overview of the clinical evidence. Fundam. Clin. Pharmacol.,  2005, 19(1), 1-16.
 [http://dx.doi.org/10.1111/j.1472-8206.2004.00301.x] [PMID:  15660956]

[133]
Kim, K.N.; Ko, Y.J.; Yang, H.M.; Ham, Y.M.; Roh, S.W.; Jeon, Y.J.; Ahn, G.; Kang, M.C.; Yoon, W.J.; Kim, D.; Oda, T. Anti-inflammatory effect of essential oil and its constituents from fingered citron (Citrus medica L. var. sarcodactylis) through blocking JNK, ERK and NF-κB signaling pathways in LPS-activated RAW 264.7 cells. Food Chem. Toxicol.,  2013, 57, 126-131.
 [http://dx.doi.org/10.1016/j.fct.2013.03.017] [PMID:  23541436]

[134]
Kalariya, M.V.; Prajapati, R.P.; Chavda, J.R. Pharmacognostic and phytochemical evaluation of Bijapur (Citrus medica Linn.) fruit. J. Pharmacogn. Phytochem.,  2019, 8(3), 4159-4164.

[135]
Frid, P.; Xu, H.; Mitchell, B.D.; Drake, M.; Wasselius, J.; Gaynor, B.; Ryan, K.; Giese, A.K.; Schirmer, M.; Donahue, K.L.; Irie, R. Bouts; M.; McIntosh, E.C.; Mocking, S.; Dalca, A.V.; Giralt-Steinhauer, E.; Holmegaard, L.; Jood, K.; Roquer, J.; Cole, J.W.; McArdle, P. F.; Broderick, J.P.; Jimenez-Conde, J.; Jern. C.; Kissela, B.M.; Kleindorfer, D.O.; Lemmens, R.; Meschia, J.F.; Rosand, J.; Rundek, T.; Sacco, R.L.; Schmidt, R.; Sharma, P.; Slowik, A.; Thijs, V.; Woo, D.; Worrall, B.B.; Kittner, S.J.; Petersson, J.; Golland, P.; Wu, O.; Rost N.S.; Lindgren, A. Migraine-associated common genetic variants confer greater risk of posterior vs. anterior circulation ischemic stroke. J. Stroke Cerebrovasc. Dis.,  2022, 31(8), 106546.
 [http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106546] [PMID:  35576861]

[136]
Chahine, S.; Wanna, S.; Salameh, P. Migraine attacks among Lebanese university medical students: A cross sectional study on prevalence and correlations. J. Clin. Neurosci.,  2022, 100, 1-6.
 [http://dx.doi.org/10.1016/j.jocn.2022.03.039]

[137]
Furman, J.M.; Marcus, D.A.; Balaban, C.D. Vestibular migraine: clinical aspects and pathophysiology. Lancet Neurol.,  2013, 12(7), 706-715.
 [http://dx.doi.org/10.1016/S1474-4422(13)70107-8] [PMID:  23769597]

[138]
Wilbanks, C. Migraine in Adult Primary Care. J. Nurse Pract.,  2022, 18(4), 366-369.
 [http://dx.doi.org/10.1016/j.nurpra.2022.01.018]

[139]
Mykland, M.S.; Uglem, M.; Neverdahl, J.P.; Øie, L.R.; Meisingset, T.W.; Dodick, D.W.; Tronvik, E.; Engstrøm, M.; Sand, T.; Omland, P.M. Sleep restriction alters cortical inhibition in migraine: A transcranial magnetic stimulation study. Clin. Neurophysiol.,  2022, 139, 28-42.
 [http://dx.doi.org/10.1016/j.clinph.2022.04.004] [PMID:  35490438]
Cite As
Current Molecular Pharmacology

Preventive and Therapeutic Aspects of Migraine for Patient Care: An Insight

Abstract

Graphical Abstract
